Varma T R
Department of Obstetrics and Gynaecology, St George's Hospital Medical School, London, England.
Drugs Aging. 1992 May-Jun;2(3):174-95. doi: 10.2165/00002512-199202030-00003.
Menopause and hormone replacement therapy (HRT) continue to be controversial subjects. The main concern is the potential risk of prolonged HRT and the possible development of endometrial and breast carcinoma. There is no obvious evidence at present to suggest that HRT increases endometrial carcinoma provided the patient receives progestogen for a period of 10 or more days (usual period is 12 days) during each month. However the breast does not seem to enjoy this safety margin and there is some concern about possible increase in the incidence of breast cancer if the treatment period is longer than 5 years. The increase in the risk is higher after 15 years of estrogen use. There is no obvious adverse effect on the ovary or on the cervix following HRT.
更年期及激素替代疗法(HRT)仍然是备受争议的话题。主要担忧在于长期使用HRT的潜在风险以及子宫内膜癌和乳腺癌可能的发生。目前尚无明显证据表明,只要患者每月接受孕激素治疗10天或更长时间(通常为12天),HRT就会增加子宫内膜癌的风险。然而,乳腺似乎没有这样的安全界限,并且有人担心,如果治疗期超过5年,乳腺癌的发病率可能会增加。使用雌激素15年后风险增加更高。HRT对卵巢或宫颈没有明显的不良影响。